Patient education › Bladder cancer
Bladder cancer
Bladder cancer is usually found because of blood in the urine, and almost everything that follows depends on one question: has it grown into the muscle wall or not.
Walk in prepared
Bladder cancer generates a lot of appointments over a lot of years. Being organized from the start pays off repeatedly.
Dr. Weiner uses WellPrept to help patients gather their records and write down their questions ahead of time. It is free, takes about ten minutes, and you do not need to be his patient to use it. If you are seeing another urologist, or preparing for a second opinion anywhere, it works just as well.
Organize your records and questions before you sit down. Free, and yours to keep whichever doctor you see.
Blood in the urine is the reason to look
The commonest first sign is blood in the urine. It is usually painless, and it very often stops on its own. Stopping is not reassurance. A single episode of visible blood in the urine deserves a proper evaluation, and so does blood found only under a microscope on a routine test.
A full workup normally means a CT scan that images the kidneys and drainage system with contrast, a look inside the bladder with a small camera passed through the urethra, and a urine sample examined for cancer cells. The camera examination is called cystoscopy, is done awake in the office, and is uncomfortable rather than painful.
Smoking is the dominant cause
Smoking is by a wide margin the biggest risk factor for bladder cancer, and it is the second most common tobacco-related cancer. This matters after diagnosis, not just before it: continuing to smoke is linked to the cancer coming back and to worse outcomes from treatment. Guidelines specifically recommend cessation support as part of treatment, and there is good evidence that a cancer diagnosis is one of the moments people most often succeed in quitting.
Muscle invasion changes everything
Roughly three quarters of bladder cancers have not grown into the muscle wall at diagnosis. That group is managed through the urethra, over years. The rest need much more.
Non-muscle-invasive
Treated by removing tumours through the urethra, often with medicine placed directly into the bladder, and followed with regular camera checks. The bladder stays. The trade-off is that this disease recurs often, so surveillance is long-term.
Muscle-invasive
Needs treatment aimed at cure: chemotherapy followed by removing the bladder, or a bladder-preserving combination of resection, chemotherapy and radiation. Delay here genuinely costs.
Risk group drives everything
Once the pathology is back, your cancer is sorted into low, intermediate or high risk. Grade, stage, size, how many tumours there were, whether it has come back before, and whether flat carcinoma in situ is present all feed in. Importantly, that grouping is reassessed every time the cancer recurs, so your risk category can move.
Medicine put into the bladder
For low-risk disease, a single dose of chemotherapy instilled into the bladder within a day of the resection meaningfully reduces the chance of recurrence, and nothing further is usually needed. Intermediate-risk disease may be offered a six-week course. High-risk disease is offered BCG, an immune-stimulating treatment given weekly for six weeks and then, if it works, in shorter maintenance courses over about three years. Maintenance is what makes the difference; a single induction course alone is less effective.
BCG is not gentle. Most people get some urinary symptoms or flu-like effects, and a minority stop because of them. Tell your team early if you are struggling, because dose and timing can often be adjusted.
If BCG does not work
Some cancers come back despite adequate BCG. If it recurs early after two proper courses, more BCG is not the answer. Options then include a clinical trial, newer treatments instilled into the bladder, or immunotherapy given intravenously. Removing the bladder remains the most reliable cancer control, and for high-grade disease that persists it deserves serious discussion rather than being treated as failure.
The second look
If the first resection did not include muscle, or could not remove everything, or the cancer was staged T1, a repeat resection within about six weeks is standard. It changes the stage in a meaningful minority of people, and finding out now is far better than finding out later.
Surveillance
Everyone gets a camera check about three to four months after treatment. After that the interval depends on risk: low-risk disease stretches out to annual checks fairly quickly, while high-risk disease stays on a three to four month schedule for the first couple of years. Intermediate and high-risk patients also have their kidneys and ureters imaged periodically, because the same cell type can appear higher in the urinary tract.
Chemotherapy first, then a choice
For muscle-invasive disease that has not spread, the standard of care is cisplatin-based chemotherapy before surgery, not after. This is one of the clearest recommendations in the field: giving chemotherapy first improves survival, and the benefit is lost if fewer than three cycles are given or if a non-cisplatin drug is substituted. Surgery follows within a few weeks of finishing.
Not everyone can have cisplatin. Reduced kidney function, being less physically robust, significant heart failure, existing hearing loss or nerve damage in the hands and feet can all rule it out, and that applies to a sizeable minority of patients. Carboplatin is not an acceptable substitute in this setting, so those patients move to definitive treatment or a trial instead.
Removing the bladder
Radical cystectomy removes the bladder along with nearby organs, and always includes removing the pelvic lymph nodes on both sides. That node dissection is not optional and it is how the true stage is established.
Your urine then needs a new route out, and there are three options that should all be discussed with you rather than one being assumed. An ileal conduit uses a short piece of bowel to drain urine continuously into a bag on the abdomen; it is the simplest and most common. A neobladder builds a new reservoir from bowel and connects it to the urethra, so you pass urine more normally, though continence takes work and is rarely perfect at night. A continent cutaneous reservoir is an internal pouch you empty several times a day with a catheter through a small opening. Kidney function, liver function, bowel available, where the cancer sits, and your willingness to self-catheterize all narrow the choice.
Keeping the bladder
Trimodal therapy is a genuine alternative for selected people: the most complete resection possible, then radiation given together with radiosensitizing chemotherapy, then lifelong bladder surveillance. It suits patients whose tumour can be fully resected, who do not have carcinoma in situ or a blocked kidney, and whose disease is not too advanced locally. It is also the right answer for people who cannot safely have major surgery. Radiation on its own is not curative treatment. If muscle-invasive cancer returns afterwards, removing the bladder is still on the table.
Cystectomy is major surgery. Complications within three months are common even at experienced centres, and risk climbs with age. That is an argument for going to a high-volume team and for getting fitter beforehand, including stopping smoking, not an argument for avoiding treatment that is intended to cure you.
Worth asking out loud
Bladder cancer means a long relationship with a urology team. Start it well.
About the diagnosis
- Was muscle present in my TURBT specimen?
- What grade and stage is my tumour, and is there carcinoma in situ?
- What risk group am I in?
- Is there any variant histology, and has a specialist pathologist confirmed it?
- Do I need a repeat resection?
About treatment
- Should I be having medicine put into my bladder, and which?
- If BCG, will I get maintenance, and for how long?
- If my cancer is muscle-invasive, am I fit for cisplatin?
- Is bladder preservation an option for me?
- What happens if the first treatment does not work?
About living with it
- How often will I need cystoscopy, and for how many years?
- What help can you give me to stop smoking?
- Will my kidneys be checked as well as my bladder?
- What symptoms should make me call you sooner?
About surgery, if it comes to that
- Which urinary diversion suits me, and why?
- What does recovery actually look like, week by week?
- How will this affect sexual function?
- Would a second opinion at a high-volume centre be reasonable?
Sources and further reading
This page was written for patients and reviewed by Dr. Weiner. It reflects current professional guidelines, which are written for clinicians. The patient-facing versions below are free and often easier to read.
- Non-Muscle-Invasive Bladder Cancer: AUA/SUO Guideline, American Urological Association.
- Muscle-Invasive Bladder Cancer: AUA/ASCO/SUO Guideline, American Urological Association.
- Bladder Cancer Patient Guide, Urology Care Foundation.
- Urology Care Foundation, the AUA's patient education arm.
- NCCN Guidelines for Patients, free plain-language versions of the treatment guidelines.
This is general education, not medical advice. It cannot account for your imaging, your pathology, your other health conditions or what matters to you. Take it to your own doctor and work through it together. If anything here conflicts with what your urologist has told you, raise it with them directly rather than assuming either of us is wrong.
Last reviewed September 2026 by Adam B. Weiner, MD.